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Antiparaoxon immune sera were employed in a new immunoassay based on competition between acetylcho- 
linesterase and antibodies for the binding of paraoxon. Unlike radioimmunoassay, the new assay described 
herein can be extended to predict the feasibility of antibodies to confer in vivo protection of acetylcholin- 
esterase against organophosphate poisoning. The toxicity of paraoxon was reduced in mice which were pre- 
injected with the immune sera. 
Organophosphate Immunization Acetylcholinesterase 
Antiparaoxon antibody Immunoassay 
Paraoxon 
1 _ INTRODUCTION 
Organophosphorus compounds are widely used 
as insecticides. Accidental exposure of humans and 
domestic animals to such insecticides results in a 
potentially lethal cholinergic poisoning [ 1). An- 
tidotal treatment with atropin and cholinesterase 
reactivators is not always effective in cases of acute 
poisoning and rarely, if at all, in some forms of 
delayed effects [2]. The use of prophylaxis might 
therefore be advisable in some vulnerable 
populations. 
Organophosphorus insecticides inhibit acetyl- 
cholinesterase (AChE). It is this inhibition that is 
thought to produce their highly toxic effects. Since 
the affinity of organophosphates towards AChE is 
relatively high [3], it may be questioned whether 
antibodies could efficiently compete with the en- 
zyme for the binding of organophosphorus com- 
pound. Successful competition may possibly con- 
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fer protection against poisoning and make im- 
munization a potential prophylactic tool. The pro- 
duction of antibodies against organophosphorus 
compounds has been described [4-61. However, 
one cannot predict as yet how efficient these anti- 
bodies would be in reducing the toxicity of organo- 
phosphates. We thought that since AChE inhibi- 
tion can be measured in vitro, a concurrent in vitro 
measurement of the enzyme protection by anti- 
bodies might serve as a meaningful indicator for in 
vivo protection. To test this hypothesis we prepared 
antibodies against paraoxon (the oxidized form of 
the insecticide parathion), which is a potent in- 
hibitor of AChE [7] and examined their abiIity to 
protect the enzyme (AChE) from inhibition by this 
organophosphate. We then tested whether in vivo 
results would be consistent with our in vitro data. 
2. MATERIALS AND METHODS 
2.1. Animals 
New Zealand white rabbits were used for 
preparation of antibodies. ICR mice weighing 
20-24 g were used to test in vivo toxicity and pro- 
tection by antibodies. 
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2.2. Preparation of immunogens 
Two different paraoxon derivatives conjugated 
with a protein carrier were employed in the present 
studies: 
I? 
Conjugate a NO2 
O - P - OCzH5 
BSA 
Conjugate a was prepared from 0-(4-nitro- 
phenyl)-O-ethyl phosphorochloridate which was 
added to a solution of bovine serum albumin 
(BSA) in 0.1 N Tris buffer (pH 8.8). The 0-(4- 
nitrophenyl)-O-ethyl phosphorochloridate was 
prepared by reacting 4-nitrophenyl phosphoro- 
chloridate with an equimolar amount of ethanol in 
the presence of pyridine. This compound was iden- 
tified by 31P- and ‘H-NMR. 
- 0 
Conjugate b NO2 
-0- 
-‘: 
o I 
- oc2ti5 
NHCH2CH2COOUSA 
Conjugate b was prepared from the correspon- 
ding active ester which was added to BSA in 0.1 N 
NaHCO3 (pH 6.7). The corresponding active ester 
was prepared by reacting equimolar amounts of 
the corresponding acid with N-hydroxysuccinimide 
and dicyclohexylcarbodiimide. The product was 
purified on a silica gel column eluted with 
chloroform: hexane (1: 1) and identified by 31P- 
and ‘H-NMR and mass spectrometry. 
The corresponding acid was prepared by cou- 
pling 0-(4-nitrophenyl)-O-ethyl phosphorochlori- 
date and the trimethylsilyl ester of N-trimethyl-fl- 
alanine in the presence of triethylamine. The pro- 
duct was recovered from the reaction mixture and 
analyzed by 31P- and ‘H-NMR. 
Both conjugates were separated from the reac- 
tants on Sephadex G-25. Protein [8] and phosphate 
determinations [9] showed that conjugate a con- 
tains 29 hapten residues per BSA molecule, while 
conjugate b contains 40 hapten molecules per BSA 
molecule. Rabbit serum albumin (RSA)-paraoxon 
conjugates were prepared in the same manner as 
the BSA-paraoxon conjugates described above. 
2.3. Preparation of antibodies 
The antibodies were produced by injection of 
the antigens described above into 10 intradermal 
sites (2 mg protein emulsified in a complete Freund 
adjuvant, 1: 1); 4 booster injections were given at 
2-4 weeks intervals. Immune sera were collected 
10 days following the last injection. 
For this study, we used two antisera, each of 
which was collected from different rabbits. No.1 
was injected with conjugate a, and no.2 with con- 
jugate b. Determination of the amount of the 
specific antibodies in these antisera by a quan- 
titative precipitation [lo], using RSA-paraoxon 
conjugate, showed no preference for either of the 
two antigens described above. In preliminary ex- 
periments, we found that paraoxon-inactivating 
enzymes which are present in rabbit sera [ 11) could 
be destroyed by heating the sera to 64°C for 1 h. 
This treatment, which prevented the destruction of 
paraoxon, did not affect the binding ability of IgG 
[12] and thus increased the observed binding of 
[3H]paraoxon from 27% with unheated immune 
sera to 60% with the heated immune sera. Heated 
sera were therefore used in our studies. 
2.4. Radioimmunoassay (RIA) 
RIA was performed by determining the amount 
of [3H]paraoxon ([phenyl-3-3H]-, 1.3 Ci/mmol) 
bound to the antisera in the presence of various 
concentrations of unlabelled hapten. The reaction 
mixture for the binding assay contained 10~1 of 
the tested serum, 90~1 of 3% BGG, 100~1 
[3H]paraoxon (prediluted 1: 2000) and 300 pl 
saline. After 30 min incubation at 37°C and conse- 
quent ammonium sulphate precipitation, the 
bound counts were determined in the pellet. 
2.5. Enzyme-antibody competition assay (EACA) 
The reaction mixture (100~1) contained the 
following: 100 mM Tris buffer, pH 7.4, containing 
2 mM NaCl, 0.2 units AChE (purified from elec- 
tric eel with a specific activity of 1641 units/mg 
protein), 10~1 immune or control serum (their 
cholinesterase activity was completely inactivated 
prior to the assay) and various concentrations of 
paraoxon as described for each particular 
experiment. 
Incubation of the reaction mixture was at 25°C 
for 10 min. In some cases the serum was added 
5 min prior to the addition of AChE, while in 
others the serum and AChE were added 
simultaneously. A second incubation for an addi- 
tional 10 min was then carried out following the 
addition of [3H]acetylcholine chloride ([3H]ACh, 
500 pCi/mmol). 
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The reaction was terminated by the addition of 
100~1 chloroacetic acid (1 M) cont~ning 0.5 M 
NaOH and 2 M NaQ. The [3Hlacetate, which was 
hydrolyzed during the incubation, was then ex- 
tracted into a scintillation liquid 1131 and its 
radioactivity determined. The differences between 
the amounts of [jH]acetate liberated in the 
presence of control serum and those liberated in 
presence of immune serum (at the same concentra- 
tion of paraoxon) were used to calculate the 
amount of the paraoxon which was inactivated by 
the immune serum. 
2.6. Toxicity determinations 
Four groups of mice (16 animals in each) were 
used for toxicity and protection tests. The first 
group did not receive any treatment except for 
poisoning with paraoxon. The other 3 groups were 
80 
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injected intravenously (i.v.) with either non- 
immune or one of the immune sera {OS ml). 
Paraoxon was administered subcutaneousiy (s.c.), 
15 min following the injection of the sera. Before 
challenging, each of the groups were divided into 
4 subgroups (n = 4), each of which received a dif- 
ferent dose of paraoxon. The L&O values were 
calculated according to Weil [14]. 
3. RESULTS 
As can be seen from fig.1, antibodies prepared 
from immune rabbits were specific for paraoxon 
without cross-reactivity with p-nitrophenol or 
diethyl phosphate. Parathion, which is structurally 
related to paraoxon, was also recognized by these 
antibodies. The lowest limit of detection with these 
antibodies was 300 pg paraoxon (-1 pmol). 
0 0 
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concentration of hopten (pmolesl 
Fig.1. Standard curves for radioimmunoassay of paraoxon and related compounds. 20~1 of a 1: 5 dilution of 
antiparaoxon sera (from a rabbit which was immunized with antigen a) were preincubated for 30 min at 37°C with 
100 ~1 [3H]paraoxon (10000 cpm; 0.8 x lOA M). 100 pl of various concentrations of unlabelled hapten (as indicated 
by the formula for each curve on the graph) were then added together with 80 ~1 of 20% normal sheep serum and 200 pl 
of 0.9Yo NaCl and incubated at 2YC for l-2 h. ~tigen-anti~dy complex was then precipitated with 50% a~onium 
sulfate, washed twice and counted. 
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The ability of the antisera to prevent paraoxon 
from inhibiting AChE was then tested. It was 
found that the inhibition of AChE by paraoxon 
was significantly reduced if the organophosphate 
had been preincubated with immune sera as com- 
pared to normal sera (fig.2A). From the maximal 
difference in the inhibitions produced by the 
LETTERS January 1985 
various concentrations of paraoxon preincubated 
with normal vs immune sera (inset of fig.2A), it 
was possible to calculate both the amount of 
paraoxon bound and the concentration of the an- 
tibodies in the immune serum. 
Comparison of these data with 
by the RIA showed that the two 
those obtained 
techniques are 
l serum from immune rabbit No I 
A eerum from wnmune rabblt No 2 
q serum from non unmune rabbit 
10-T 10-6 10-5 
concentration of paraoxon (M) 
Fig.2. The prevention of paraoxon-elicited enzyme inhibition by antiparaoxon immune sera. (A) Rabbit sera [either 
normal (0); or immune for conjugate a (A), and conjugate b (o)] were preincubated with various concentrations of 
paraoxon for 5 min at 25°C. AChE was then added and an additional 10 min incubation was carried out. The 
differences between the inhibitions of AChE obtained with non-immune vs immune sera are given in the inset. (B) 
Rabbit sera (same as in A) and AChE were simultaneously incubated with various concentrations of paraoxon for 
10 min at 25°C. Activities of AChE in both cases (A,B) were determined after the addition of [3H]ACh, by measuring 
the radioactivity within [3H]acetate which was released during 10 min at 25°C. 
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compatible. Thus, the concentration of the anti- 
paraoxon specific antibodies in the immune sera 
were 78 pg/ml as calculated from the data ob- 
tained by RIA and 69 pg/ml as calculated from the 
EACA. 
Experiments in which antisera and AChE were 
exposed simultaneously to various concentrations 
of paraoxon are presented in fig.2B. As can be 
seen, the two immune sera competed successfully 
with the enzyme for the binding of paraoxon and 
reduced its inhibitory effect. These data suggest 
that the tested antibodies possess a higher affinity 
toward paraoxon than does the enzyme and that 
the paraoxon which is bound by the antibodies is 
no longer available for inhibiting AChE. 
To test the ability of the antibodies to protect 
against paraoxon poisoning in vivo, we injected 
immune sera into mice and determined the toxicity 
values of paraoxon in these animals as compared 
to naive mice or mice which were injected with 
non-immune sera. The results of these experiments 
are presented in table 1. It can be seen that the im- 
mune sera significantly reduced the toxicity of the 
paraoxon (row 3, table 1). 
However, when the maximal amounts of 
paraoxon that could have been inactivated by the 
total amount of the injected immune sera were 
calculated from our EACA data, we found that 
about 40-times more paraoxon was inactivated in 
vivo than was expected from the in vitro data (rows 
4 and 5, table 1). Therefore, we concluded that 
passive immunization can be achieved even with a 
relatively small amount of antibodies. Indeed, as 
can be seen from table 1 (rows 1 and 2), the sur- 
vival of mice which were injected with the immune 
sera and consequently poisoned with paraoxon was 
significantly higher than that of the control mice. 
We also found that in the surviving mice the signs 
of poisoning of those injected with immune sera 
were less severe than those observed in the control 
group. 
4. DISCUSSION 
The work described in this article presents the 
first direct demonstration that antibodies can suc- 
cessfully compete with AChE for binding an 
organophosphorus compound. Moreover, the 
direct measurement of enzyme protection in the 
presence of antibodies constitutes a simple and 
novel in vitro technique that can evaluate 
qualitatively the in vivo immune capacity of an im- 
munized individual. This novel immunoassay, the 
EACA, is fully compatible with the conventional 
RIA but unlike RIA can also provide information 
as to the actual potential of antibodies to confer in 
Table 1 
The ability of antisera injected intravenously to inactivate paraoxon and reduce its toxicity in vivo 
Parameter measured 
No serum 
Type of serum injected 
Control serum Antiserum from Antiserum from 
(non-immune) rabbit no. 1 rabbit no.2 
Survival ratio with 700 pg/kg 
paraoxon 
Survival ratio with 800,uglkg 
paraoxon 
LDso values and their 95% 
confidence limits (in parentheses) 
Extra amount of paraoxon (ng) 
needed to reach LDSO in the 
experimental groups 
Amount of paraoxon (ng) 
inactivated by 0.5 ml sera as 
determined in vitro by EACA 
2/4 l/4 4/4 
o/4 o/4 3/4 4/4 
684.3 632.8 888.0 1007.1 
(625.0-749.2) (566.3-707.1) 714.7-I 103.4) 875.5-1158.6) 
0 4590 6970 
0 144 180 
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vivo protection against organophosphorus poison- 
ing. In vivo protection should not be expected in 
cases where antibodies would only bind 
organophosphorus compounds (as can be deter- 
mined by both RIA and EACA), but would not be 
able to ccmpete successfully with AChE (as can be 
found only by EACA). 
Our study clearly indicates that in vivo protec- 
tion was achieved when the EACA demonstrated 
that possibility. However, a significant quan- 
titative difference was found when the ability of 
the antibodies to bind and inactivate paraoxon in 
vitro (EACA) was compared to their ability to pro- 
tect animals against paraoxon poisoning in vivo. 
A larger amount of paraoxon was inactivated in 
vivo than could have been expected from the 
EACA. This difference can be explained if we take 
into account that only a small fraction of the in- 
jected paraoxon reached the target sites responsi- 
ble for the cholinergic poisoning. Most of the in- 
jected paraoxon is probably destroyed by en- 
dogenous hydrolytic activity and by binding to 
‘non-specific’ sites, before reaching those targets. 
From our data it is possible to estimate that no 
more than 3-5% of the injected paraoxon reaches 
the ‘target sites’, and if so, it would be safe to 
assume that active immunization against paraoxon 
would be even more efficient in the protection 
against poisoning than the passive immunization 
tested there. 
By using the EACA it will be possible to deter- 
mine whether an immune subject is potentially im- 
mune to organophosphate poisoning and to 
estimate roughly the degree of protection that 
should be expected in this immune individual. 
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